CD274 and neoplasm: This immunogenic cascade allows ICIs, including PD-1/PD-L1 inhibitors or CTLA-4 blockers, to strengthen antitumour immune responses by lifting inhibitory breaks in T cells, promoting the proliferation of cytotoxic T-cell populations, and increasing recognition and clearance of both antigen-positive and -negative tumour subclones [119].